Bimagrumab

Bimagrumab
Monoclonal antibody
Type?
SourceHuman
TargetACVR2B
Clinical data
Other namesBYM338
Routes of
administration		Intravenous
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6306H9732N1684O1990S46
Molar mass142451.78 g·mol−1

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.[1]

Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month.[2]

  1. ^ Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. (June 2018). "Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes". Clinical Endocrinology. 88 (6): 908–919. doi:10.1111/cen.13601. PMID 29566437. S2CID 5019650.
  2. ^ Cite error: The named reference GlobalData Healthcare_2023 was invoked but never defined (see the help page).
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.